NCT00092404View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

PHASE2CompletedINTERVENTIONAL

Enrollment

1,210

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions

MeaslesMumpsRubellaVaricella

Interventions

BIOLOGICAL

measles, mumps, and rubella virus vaccine live

BIOLOGICAL

Comparator: Measles, Mumps, and Rubella Virus Vaccine Live

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092404 - Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) | Biotech Hunter | Biotech Hunter